| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_331e38ffbbd507f0d1394c4b56600dca
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_35b201f4271b13efe729822eb75754ac
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_3e8aa04ddbb96c8a28737cd7b9f83fb2
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_6ac5b3316258a79625ddd3adbe361b60
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_8d0564ae53d6d3b82a5478e0bfd949a0
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_58835f3078705c36566a7af78a41202c |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D513-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-554
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D513-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 |
| filingDate |
2012-05-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_cb92d26540e73a09ddae97806bd9bea8
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1d64beab23f4f4c1ada824210c10ae64
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c69b456a6056fe5d8cd310bd4144c8f4
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7a0c4ff2752a512d92773557cc05ef3d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_72c9b67c9c47619b18cf9a11ba8501d7 |
| publicationDate |
2012-12-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2012163236-A1 |
| titleOfInvention |
Pyridothiazepine derivative, preparation method and uses therefor |
| abstract |
The present invention belongs to the field of medicine and relates to a pyridothiazepine derivative and a preparation method and uses therefor. Pyridothiazepine derivatives have a wide range of antineoplastic activity, said compounds exhibiting excellent inhibitive effect on various human carcinoma cell lines in in vitro cell tests; said cell lines include human leukemia cell line OP-1, human colon carcinoma cell line HT29, human lung carcinoma cell line H460, paclitaxel-resistant human lung carcinoma cell line H460TaxR, and doxorubicin-resistant human breast carcinoma cell line MCF-7/Adr. The compounds can independently or together with active ingredients of other anticancer drugs be mixed with pharmaceutical excipients to form a pharmaceutical formulation that can be used to treat various carcinomas. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2014029250-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-112891377-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-112891377-B |
| priorityDate |
2011-05-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |